8 (3.1) days. Most patients were sent home (62%) after hospital discharge. These findings add substantially to the literature regarding

the effectiveness of ceftaroline in patients with renal dysfunction. However, consistent with the other subgroup analyses, the limited sample size and the potential for selection bias necessitate the need for additional verification prior to routine use in clinical practice. Another area of interest for clinicians is the ability of ceftaroline to treat MRSA CABP. Patients with MRSA CABP were specifically excluded from the FOCUS trials due to the inactivity of ceftriaxone against MRSA [2–4]. CAPTURE has afforded an opportunity to examine the use of ceftaroline for patients with CABP with positive cultures for MRSA [6]. SN-38 At the time of abstract presentation in 2013, there were a total of 39 patients with CABP with positive cultures for MRSA in CAPTURE. With regard to culture sites, MRSA was isolated from both blood and respiratory samples in three patients

(8%), respiratory samples only in 28 patients (72%), and blood samples only in 8 patients (21%). The cohort of patients with CABP with a positive MRSA culture was predominately male (n = 25, 64%) and the mean (SD) age was 59.0 (16.6) years. Similar to the other subgroups www.selleckchem.com/products/gsk3326595-epz015938.html examined, comorbidities were highly prevalent. Thirty-three patients (85%) had comorbidities including structural lung disease (56.4%), GERD (33.3%), history of smoking (25.6%), prior pneumonia (20.5%), and CHF (18.0%). There was an equal proportion of patients admitted to intensive care units and general practice units (51% vs. 49%). Nearly all patients (n = 36, 92%) received prior antibiotics before initiation of ceftaroline. Glycopeptides, cephalosporins, and penicillins were the most commonly used prior antibiotics (67%, 31%, and 31%, respectively). Half the patients (n = 20) received ceftaroline

as monotherapy, while the remainder received concurrent gylcopeptides (28%), quinolones (15%), and macrolides Mirabegron (8%). Patients were treated for a mean (range) of 7.3 days (range 1–30 days). The incidence of clinical success was 62% (n = 24). Similar to other investigations, clinical success was greater in those admitted to the general practice units relative to the ICU (74% vs. 50%, respectively). Source of pathogen isolation did not affect clinical cure (respiratory: 61%, blood: 64%). Ceftaroline monotherapy was associated with higher rates of clinical success as compared to combination therapy (75% vs 47%). Among those with a clinical failure, two patients were transferred to hospice care and one patient had a lobectomy due to a lung abscess. A high proportion of patients were discharged home (46%), while fewer were discharged to another care facility (44%).